Abstract
Antifungal prophylaxis in the haematological patient is currently regarded as the gold standard in situations with a high risk of infection, such as acute leukaemias, myelodysplastic syndromes and autologous or allogenic hematopoietic stem cell transplantation. Over the years, different scientific societies have established a series of recommendations on antifungal prophylaxis based on prospective studies performed with different drugs. However, the prescription of each one of the agents must be personalised, adapted to the characteristics of each patient and to possible interactions with concomitant medication.
MeSH terms
-
Algorithms
-
Amphotericin B / therapeutic use
-
Antifungal Agents / adverse effects
-
Antifungal Agents / pharmacokinetics
-
Antifungal Agents / therapeutic use*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / therapeutic use
-
Biological Availability
-
Decision Trees
-
Drug Interactions
-
Echinocandins / therapeutic use
-
Hematologic Neoplasms / complications*
-
Hematologic Neoplasms / drug therapy
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Immunocompromised Host
-
Immunosuppressive Agents / pharmacokinetics
-
Immunosuppressive Agents / therapeutic use
-
Liver Diseases / complications
-
Mycoses / etiology
-
Mycoses / prevention & control*
-
Myelodysplastic Syndromes / complications*
-
Postoperative Complications / etiology
-
Postoperative Complications / microbiology
-
Postoperative Complications / prevention & control*
-
Practice Guidelines as Topic
-
Premedication*
-
Triazoles / adverse effects
-
Triazoles / pharmacokinetics
-
Triazoles / therapeutic use
Substances
-
Antifungal Agents
-
Antineoplastic Agents
-
Echinocandins
-
Immunosuppressive Agents
-
Triazoles
-
liposomal amphotericin B
-
Amphotericin B